A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis

Pertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization...

Full description

Bibliographic Details
Main Authors: Jingjing Gao, Linlin Huang, Shuquan Luo, Ruijie Qiao, Fanglei Liu, Xin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124695/full
_version_ 1797838673957355520
author Jingjing Gao
Linlin Huang
Shuquan Luo
Ruijie Qiao
Fanglei Liu
Xin Li
Xin Li
author_facet Jingjing Gao
Linlin Huang
Shuquan Luo
Ruijie Qiao
Fanglei Liu
Xin Li
Xin Li
author_sort Jingjing Gao
collection DOAJ
description Pertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization and transmission of B. pertussis, causing a resurgence of pertussis, so improved pertussis vaccines are urgently needed. In this study, we created a two-component pertussis vaccine candidate containing a conjugate prepared from oligosaccharides and pertussis toxin. After demonstrating the ability of the vaccine to induce a mixed Th1/Th2/Th17 profile in a mouse model, the strong in vitro bactericidal activity and IgG response of the vaccine were further demonstrated. In addition, the vaccine candidate further induced efficient prophylactic effects against B. pertussis in a mouse aerosol infection model. In summary, the vaccine candidate in this paper induces antibodies with bactericidal activity to provide high protection, shorten the duration of bacterial existence, and further reduce disease outbreaks. Therefore, the vaccine has the potential to be the next generation of pertussis vaccines.
first_indexed 2024-04-09T15:44:39Z
format Article
id doaj.art-da8d23b99b8542aeac285045f9baa956
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-09T15:44:39Z
publishDate 2023-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-da8d23b99b8542aeac285045f9baa9562023-04-27T04:51:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11246951124695A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussisJingjing Gao0Linlin Huang1Shuquan Luo2Ruijie Qiao3Fanglei Liu4Xin Li5Xin Li6The First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaThe First R&D Laboratory, Lanzhou Institute of Biological Products Company Limited, Lanzhou, ChinaState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, ChinaPertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization and transmission of B. pertussis, causing a resurgence of pertussis, so improved pertussis vaccines are urgently needed. In this study, we created a two-component pertussis vaccine candidate containing a conjugate prepared from oligosaccharides and pertussis toxin. After demonstrating the ability of the vaccine to induce a mixed Th1/Th2/Th17 profile in a mouse model, the strong in vitro bactericidal activity and IgG response of the vaccine were further demonstrated. In addition, the vaccine candidate further induced efficient prophylactic effects against B. pertussis in a mouse aerosol infection model. In summary, the vaccine candidate in this paper induces antibodies with bactericidal activity to provide high protection, shorten the duration of bacterial existence, and further reduce disease outbreaks. Therefore, the vaccine has the potential to be the next generation of pertussis vaccines.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124695/fullBordetella pertussislipooligosaccharidesconjugate vaccinepertussis toxinProtection
spellingShingle Jingjing Gao
Linlin Huang
Shuquan Luo
Ruijie Qiao
Fanglei Liu
Xin Li
Xin Li
A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
Frontiers in Immunology
Bordetella pertussis
lipooligosaccharides
conjugate vaccine
pertussis toxin
Protection
title A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
title_full A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
title_fullStr A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
title_full_unstemmed A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
title_short A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
title_sort novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against bordetella pertussis
topic Bordetella pertussis
lipooligosaccharides
conjugate vaccine
pertussis toxin
Protection
url https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124695/full
work_keys_str_mv AT jingjinggao anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT linlinhuang anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT shuquanluo anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT ruijieqiao anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT fangleiliu anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT xinli anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT xinli anovelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT jingjinggao novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT linlinhuang novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT shuquanluo novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT ruijieqiao novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT fangleiliu novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT xinli novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis
AT xinli novelvaccineformulationcandidatebasedonlipooligosaccharidesandpertussistoxinagainstbordetellapertussis